These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31289198)

  • 41. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas.
    Otsuka Y; Nishikori M; Arima H; Izumi K; Kitawaki T; Hishizawa M; Takaori-Kondo A
    Mol Immunol; 2020 Mar; 119():35-45. PubMed ID: 31962268
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
    Konze KD; Ma A; Li F; Barsyte-Lovejoy D; Parton T; Macnevin CJ; Liu F; Gao C; Huang XP; Kuznetsova E; Rougie M; Jiang A; Pattenden SG; Norris JL; James LI; Roth BL; Brown PJ; Frye SV; Arrowsmith CH; Hahn KM; Wang GG; Vedadi M; Jin J
    ACS Chem Biol; 2013; 8(6):1324-34. PubMed ID: 23614352
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.
    Lim SL; Xu L; Han BC; Shyamsunder P; Chng WJ; Koeffler HP
    PLoS One; 2020; 15(6):e0232068. PubMed ID: 32559187
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.
    Preston SEJ; Emond A; Pettersson F; Dupéré-Richer D; Abraham MJ; Riva A; Kinal M; Rys RN; Johnson NA; Mann KK; Del Rincón SV; Licht JD; Miller WH
    Mol Cancer Ther; 2022 Apr; 21(4):511-521. PubMed ID: 35086959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
    Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
    Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
    Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
    PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
    Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
    Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.
    Bradley WD; Arora S; Busby J; Balasubramanian S; Gehling VS; Nasveschuk CG; Vaswani RG; Yuan CC; Hatton C; Zhao F; Williamson KE; Iyer P; Méndez J; Campbell R; Cantone N; Garapaty-Rao S; Audia JE; Cook AS; Dakin LA; Albrecht BK; Harmange JC; Daniels DL; Cummings RT; Bryant BM; Normant E; Trojer P
    Chem Biol; 2014 Nov; 21(11):1463-75. PubMed ID: 25457180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
    Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
    Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes.
    Salerno D; Hasham MG; Marshall R; Garriga J; Tsygankov AY; Graña X
    Gene; 2007 Dec; 405(1-2):65-78. PubMed ID: 17949927
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells.
    Shan B; Zhuo Y; Chin D; Morris CA; Morris GF; Lasky JA
    J Biol Chem; 2005 Jan; 280(2):1103-11. PubMed ID: 15528190
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
    Huang X; Yan J; Zhang M; Wang Y; Chen Y; Fu X; Wei R; Zheng XL; Liu Z; Zhang X; Yang H; Hao B; Shen YY; Su Y; Cong X; Huang M; Tan M; Ding J; Geng M
    Cell; 2018 Sep; 175(1):186-199.e19. PubMed ID: 30220457
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CDK9 a potential target for drug development.
    Canduri F; Perez PC; Caceres RA; de Azevedo WF
    Med Chem; 2008 May; 4(3):210-8. PubMed ID: 18473913
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Integrative Analysis Reveals the Transcriptional Collaboration between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression.
    Xu H; Xu K; He HH; Zang C; Chen CH; Chen Y; Qin Q; Wang S; Wang C; Hu S; Li F; Long H; Brown M; Liu XS
    Mol Cancer Res; 2016 Feb; 14(2):163-172. PubMed ID: 26659825
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.
    Yang L; Zhou F; Zhuang Y; Liu Y; Xu L; Zhao H; Xiang Y; Dai X; Liu Z; Huang X; Wang L; Zhao C
    Br J Cancer; 2021 Feb; 124(3):645-657. PubMed ID: 33122847
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.
    Gao J; Wang MY; Ren Y; Lwin T; Li T; Yan JC; Sotomayor EM; Duckett DR; Shah BD; Shain KH; Zhao X; Tao J
    Haematologica; 2022 May; 107(5):1119-1130. PubMed ID: 34162179
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma.
    Oñate-Ocaña LF; Ponce-Martínez M; Taja-Chayeb L; Gutiérrez-Hernández O; Avilés-Salas A; Cantú-de-León D; Dueñas-González A; Candelaria-Hernández M
    Rev Invest Clin; 2021 Nov; 73(6):362-370. PubMed ID: 34044429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design and Synthesis of Dual EZH2/BRD4 Inhibitors to Target Solid Tumors.
    Guo Z; Sun Y; Liang L; Lu W; Luo B; Wu Z; Huo B; Hu Y; Huang P; Wu Q; Wen S
    J Med Chem; 2022 May; 65(9):6573-6592. PubMed ID: 35500243
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
    Boiko S; Proia T; San Martin M; Gregory GP; Wu MM; Aryal N; Hattersley M; Shao W; Saeh JC; Fawell SE; Johnstone RW; Drew L; Cidado J
    Blood; 2021 May; 137(21):2947-2957. PubMed ID: 33259592
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.
    Lacrima K; Rinaldi A; Vignati S; Martin V; Tibiletti MG; Gaidano G; Catapano CV; Bertoni F
    Leuk Lymphoma; 2007 Jan; 48(1):158-67. PubMed ID: 17325859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.